Fast Forward Medical Innovation
We offer a groundbreaking innovation program in collaboration with the renowned Rogel Cancer Center.
The Rogel Cancer Center Innovation Program is an educational initiative designed to help faculty, clinicians, and research scientists develop novel therapeutics and successfully build a business case for their research to secure commercialization resources, including non-traditional funding.
The program consists of a project-based course and case study lectures from experts in the field (it is not necessary to register for the course to attend the lectures). The course will conclude with a finale pitch event in which project teams will compete for project funding.
The Rogel Cancer Center Innovation Program is a collaborative initiative with leadership and support from Innovation Partnerships and Michigan Drug Discovery.
Fast Forward Medical Innovation offers a comprehensive collection of educational programs and training tailored for busy faculty, students, clinicians, and researchers across the University of Michigan, and across the state, region, and nation.
Lecture Series - It is not necessary to be registered in the project-based course to attend the lecture series.
Director, Protein Sciences & Structural Biology
Cayman Chemical Company
Monday, April 7
10:00 AM
NCRC, Building 520, Room 1122
Cayman offers a diverse suite of specialized preclinical services, including structural biology, bioanalysis, custom assay development, medicinal chemistry, and GMP manufacturing. Their targeted and flexible approach empowers collaborators to tackle critical research questions, from basic research to drug discovery and development. This presentation will highlight specific examples of these projects.
Associate Dean for Research, College of Pharmacy
Charles R. Walgreen Jr. Professor of Pharmacy
Professor of Pharmaceutical Studies, College of Pharmacy
Friday, May 2
12:00 PM
NCRC, Building 300, Room 376
Cancer drug development suffers from a 95% failure rate over the past 40 years. Additionally, only 30% of newly approved cancer drugs meaningfully extend patients’ survival. This presentation will analyze reasons and propose possible solutions to overcome these challenges.
Research Professor, Radiology
Research Professor, Pharmacology
NEW: Monday, May 19
12:00 PM
NCRC, Building 520, Room 1122
Learn from Dr. Judy Leopold as she discusses her experience developing first-in-class cancer drug candidates throughout her career. Dr. Leopold’s work has taken her from big pharma to academia and biotech.
Project-based Course Dates – The project-based course is postponed until Fall 2025. Dates and times will be posted here when available.
The hybrid project-based course will feature a “flipped classroom” format, allowing participants the flexibility to consume learning materials at their desired pace and complete customized assignments for the individual goals of their research project. Participants will review relevant learning materials and prepare a slide deck prior to each session. During each checkpoint and coaching session, participants will present their slides and receive feedback and instruction from teaching team mentors. The course will conclude with a finale pitch event in which project teams will compete for project funding.
Who Should Apply?
Faculty clinicians, researchers, postdoctoral fellows, graduate students, and other trainees from U-M Rogel Cancer Center-affiliated labs and clinics interested in taking a deep dive into commercializing oncology therapeutics
This lecture provides an overview of current trends in oncology therapeutic discovery and development. By the end of the series, you’ll be able to:
- Outline the key stages of the oncology therapeutic discovery process
- Identify key oncology therapeutic discovery decision criteria
- Describe the importance of identifying a good oncology target
- Describe how to identify a good target
The second lecture in the series focuses on key business and commercial topics in oncology therapeutics. By the end of the lecture, you’ll be able to:
-Explain the importance of identifying unmet clinical need
-Define Target Product Profile (TPP)
-Name the key factors and considerations that comprise a TPP
-Identify the current standard of care and the market opportunity that exists within any gaps in care
-Compare and contrast the competitive advantage and the current standard of care
-Determine which commercial pathway best fits a given oncology therapeutic
In the third lecture, we’ll begin discussing pre-clinical discovery activities. By the end of this lecture, you’ll be able to:
- Explain how a target is validated pre-clinically
- Name the key components of the assay development process
- Name the key features of the selection and optimization process
- Describe the role of in vivo assays in the pre-clinical discovery process
- Explain how to select a candidate compound for further development
Lecture 4 will move from pre-clinical discovery to development. By the end of this lecture, you’ll be able to:
- Describe how to initiate and execute dosing studies
- Explain the importance of the following IND application items:
- Animal pharmacology and toxicology
- Pre-clinical data to permit assessment
The lecture series will conclude with a discussion of the clinical phase of oncology target and therapeutic development. By the end of this lecture, you’ll be able to:
- Illustrate how to design a clinical trial and outcomes
- Explain how to select the right patient population for clinical trials
Innovation Partnerships
Innovation Partnerships
Fast Forward Medical Innovation
Fast Forward Medical Innovation
Fast Forward Medical Innovation
Director, Michigan Drug Discovery
Building 520, 3rd Floor
2800 Plymouth Road
Ann Arbor, MI 48109-2800
